Breaking News, Financial News

Financial Report: Covance 1Q08

Covance

1Q Revenues: $434.0 million (+15%)

1Q Earnings: $49.1 million (+26%)

Comments: Early development revenues were $202.0 million (+13%) led by growth of toxicology and chemistry services. Operating income increased 16% to $50.6 million. Late-stage development revenues were $210.4 (+18%). Growth was led by performances in central laboratory (+30%) due to an increase in kit volumes and clinical development as well as a strengthening of the Swiss franc. Operating income was $38.9 million (+33%). Backlog at March 31, 2008 grew 20% to $2.86 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters